Literature DB >> 32251971

Audiologic testing in children with Down Syndrome: Are current guidelines optimal?

Razan A Basonbul1, Evette A Ronner2, Anni Rong3, Gina Rong3, Michael S Cohen4.   

Abstract

INTRODUCTION: Down Syndrome (DS) is a Tier 1 risk factor for hearing loss. Guidelines exist to ensure close monitoring of children with DS for hearing loss. It is important to consider the timing of testing in order to obtain meaningful audiologic data in this high-risk population. The purpose of this study is to present hearing outcomes for children with DS during the first 8 years of life and to assess these outcomes in the context of current screening guidelines.
METHODS: Retrospective review of audiometric outcomes was conducted for children with DS age 8 or younger who presented to a multidisciplinary DS clinic between January 2014 to June 2017. Age at the time of testing, as well as test success rate and hearing loss type and severity were noted.
RESULTS: 131 patients were included in the study, 52% of which were male. 36% of the patients failed their newborn hearing screening and only 9% of those subjects had normal hearing on subsequent testing. Most hearing loss identified was mild and conductive in nature. Inconclusive results were most likely to be obtained at 6-10 months of age.
CONCLUSION: Hearing loss is common among children with DS. To optimize the quality of testing and avoid the need for sedation in followup testing, routine follow-up hearing screening should be performed either before 6 months of age or after 10 months of age.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Auditory brainstem response; DS; Hearing loss; Outcomes

Year:  2020        PMID: 32251971     DOI: 10.1016/j.ijporl.2020.110017

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  1 in total

1.  Analysis of Newborn Hearing Screening Test Results of Children with Down Syndrome.

Authors:  Fatih Yüksel; Cüneyt Uğur
Journal:  Turk Arch Pediatr       Date:  2021-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.